OptimizeRx (OPRX) Expected to Announce Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) will likely be posting its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect OptimizeRx to post earnings of $0.25 per share and revenue of $30.36 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

OptimizeRx Trading Down 3.0 %

Shares of NASDAQ:OPRX opened at $4.58 on Monday. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $16.31. The company’s 50 day moving average is $5.45 and its two-hundred day moving average is $5.98. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a market cap of $84.37 million, a PE ratio of -3.44 and a beta of 1.31.

Insider Activity at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo acquired 20,000 shares of the stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $5.01 per share, with a total value of $100,200.00. Following the transaction, the chief executive officer now owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. This trade represents a 3.44 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. JMP Securities reissued a “market outperform” rating and issued a $8.00 price objective on shares of OptimizeRx in a research report on Thursday, February 6th. Stifel Nicolaus dropped their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a research report on Tuesday, December 24th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Finally, Stephens started coverage on shares of OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price on the stock. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.